Fierce Pharma

NOVEMBER 10, 2022

AstraZeneca withdraws US COVID vaccine application, shifts focus to antibody treatments. aliu. Thu, 11/10/2022 - 09:02.

363

363

MedCity News

NOVEMBER 9, 2022

More than 31% of people with employer-sponsored insurance stuck with a job they disliked for the company’s health insurance, a Forbes Advisor survey found. Another 8% of respondents left a job they liked to seek better coverage.

Insurance 133

Insurance 133

Copyright Clearance Center

NOVEMBER 7, 2022

November 7, 2022, LEHI, Utah — CloudSource+ , the newest content solution for open access materials from SirsiDynix , has integrated with Get It Now from CCC (Copyright Clearance Center) to provide immediate purchase and delivery of full-text articles to unsubscribed journals. Get It Now is used by hundreds of academic libraries around the world to help expand their virtual collections.

Sales 136

Sales Management 136

Medgadget

NOVEMBER 11, 2022

Researchers at the University of Texas at Arlington, in collaboration with Shani Biotechnologies, a local firm, have created a point-of-care device that can accurately measure hemoglobin levels and perform pulse oximetry in individuals with dark skin. At present, methods to determine hemoglobin levels at the point of care, such as pulse oximetry, are inaccurate in individuals with higher levels of melanin in their skin, and there is a clear need to develop alternatives that work for everyone.

Patients 129

Patients Medicine 129

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

Fierce Pharma

NOVEMBER 8, 2022

Moderna’s Spikevax carries higher risk of myocarditis than Pfizer's Comirnaty, study says. zbecker. Tue, 11/08/2022 - 11:03.

318

318

MedCity News

NOVEMBER 10, 2022

Sprinter Health is integrating its at-home clinical and diagnostic services into Firefly Health’s virtual primary care model. Firefly’s members will be able to receive common medical services from Sprinter clinicians in their homes — such as vital checks, blood draws, electrocardiograms, diabetic eye exams and diabetic foot screenings.

Medical 129

Medical Healthcare Healthcare 129

PharmExec

NOVEMBER 8, 2022

Why enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.

128

128

Fierce Pharma

NOVEMBER 10, 2022

Sanofi, GSK crash the COVID-19 vaccine party late with a world-first nod for their next-gen booster. fkansteiner. Thu, 11/10/2022 - 14:09.

274

274

Pharmaceutical Technology

NOVEMBER 8, 2022

Cyagen and Neurophth Therapeutics have entered a strategic partnership to jointly develop next-generation AAV gene therapy vectors for specific kinds of genetic ophthalmic ailments. According to the deal, Cyagen will leverage its artificial intelligence (AI)-driven high-throughput platform for discovering new AAV vectors with enhanced tissue targeting expertise, tissue specificity and productivity. .

Pharmaceutical 122

Pharmaceutical Patients Sales Marketing 122

pharmaphorum

NOVEMBER 6, 2022

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were mAbs and this trend is forecasted to remain the same over the next five years. Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline.

Biopharma 123

Biopharma Pharma Training Leads 123

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

MedCity News

NOVEMBER 7, 2022

In an interview, the deputy director and chief innovation officer of Translational Research Institute for Space Health, headquartered at Baylor College of Medicine, described some of the group’s work, adapting known tech for space applications and using space-based insights to improve healthcare at home.

Healthcare 120

Healthcare Healthcare Medicine 120

Fierce Pharma

NOVEMBER 7, 2022

GSK's CAR-T rival Blenrep fails multiple myeloma trial, endangering its accelerated approval. aliu. Mon, 11/07/2022 - 09:45.

271

271

PharmaVoice

NOVEMBER 11, 2022

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

Medical science 119

Medical science Medical 119

pharmaphorum

NOVEMBER 8, 2022

Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development. Ben Hargreaves examines the latest research suggesting that this transition looks set to become a permanent feature of trials in the years to come. The pharmaceutical industry’s role in developing effective vaccines against COVID-19 was a major benefit to the industry.

Patients 121

Patients Medical Pharmaceutical Healthcare 121

Advertiser: ZoomInfo

In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.

Marketing

European Pharmaceutical Review

NOVEMBER 9, 2022

Vaxxas, a biotechnology company has announced the start of its Phase I clinical trial of a needle-free COVID-19 vaccine, delivered via a high-density microarray patch (HD-MAP), giving potential coverage of all major SARS-CoV-2 variants. The COVID-19 vaccine patch is based on HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved COVID-19 vaccines.

Food and Drug Administration 118

Food and Drug Administration FDA Pharmaceutical Transportation 118

Fierce Pharma

NOVEMBER 8, 2022

Neurotech's vision loss cell therapy implant hits primary goals in phase 3 trials. ntaylor. Tue, 11/08/2022 - 06:28.

261

261

MedCity News

NOVEMBER 7, 2022

More than half, or 58%, of health plan members are “overwhelmed” when it comes to managing their health plans. Insurers need to provide information in a way that’s accessible and easy to understand, the report stated.

Insurance 117

Insurance Management 117

pharmaphorum

NOVEMBER 11, 2022

A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis – a biotech that has now been wound up – after a California court found he misrepresented the company to investors. Dr Stanley Cohen was sued by Alafi Capital and the Christopher Alafi Family Trust – the only investors in Nuredis – in 2018. The lawsuit claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for neurodegenera

FDA 113

FDA Leads Marketing 113

Advertiser: ZoomInfo

Shifting to an account-based marketing (ABM) strategy can be both exciting and challenging. Well-implemented ABM motions build engagement with high-value accounts and drive impactful campaigns that resonate with your audience. But where do you begin, and how do you progress from crawling to running? Watch now as Demand Gen experts delve into the essentials of each stage of the ABM process.

Marketing

European Pharmaceutical Review

NOVEMBER 7, 2022

Lab-grown blood cells have been transfused into a second patient in the world’s first-of-a-kind clinical trial , opening up future treatments for blood disorders such as sickle cell if found safe and effective. Stem cells from blood donors were separated and grown to produce modified red blood cells at NHS Blood and Transplant ( NHSBT ) Advanced Therapies Unit in Bristol.

Patients 112

Patients Side effects Pharmaceutical Medical 112

Fierce Pharma

NOVEMBER 10, 2022

Eli Lilly ordered to pay $177M to rival Teva in migraine patent fight. zbecker. Thu, 11/10/2022 - 11:11.

271

271

MedCity News

NOVEMBER 10, 2022

Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.

Doctors 112

Doctors Medical Marketing 112

pharmaphorum

NOVEMBER 9, 2022

Sanofi has tapped into the artificial intelligence expertise of Chinese biotech Insilico Medicine with a six-compound drug discovery collaboration that could be worth up to $1.2 billion. The alliance is backloaded, with $21.5 million paid upfront and Insilico also in line for mid-single to up to low double-digit tiered royalties for any products developed, but is comfortably the Chinese company’s largest deal to date.

Pharma 111

Pharma Pharmaceutical Medicine Leads 111

Advertiser: ZoomInfo

One of the biggest challenges for any B2B marketer is understanding your prospects’ next move — who is most likely to buy and when. Without these insights, marketing campaigns can feel more like guesswork, with high investment and little return. We’re here to tell you there’s a better way. By tracking buyers’ digital footprints and online activity, such as website visits, product reviews, and spikes in content consumption, you can engage prospects with a message that really resonates.

Marketing

Pharmaceutical Technology

NOVEMBER 9, 2022

Despite their potential multi-million-dollar sticker price, if haemophilia treatments by BioMarin and CSL Behring prove durable, they could help patients save money compared to current treatments, experts note. On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies.

Pharmaceutical 111

Pharmaceutical Patients FDA Medicine 111

Fierce Pharma

NOVEMBER 9, 2022

Troubled Clovis telegraphs bankruptcy amid FDA hardball on key cancer drug, difficulty in fundraising. aliu. Wed, 11/09/2022 - 11:33.

FDA 239

FDA 239

MedCity News

NOVEMBER 10, 2022

Aegis Ventures launched a new startup with Northwell Holdings, the venture capital arm of Northwell Health. The New York City-based company, named Upliv, focuses on virtual menopause care. It will partner with employers to provide its services to their employees at no cost.

110

110

pharmaphorum

NOVEMBER 8, 2022

For the first time, patients in England with triple-negative breast cancer (TNBC) will be able to access immunotherapy at an earlier stage of their treatment journey, as Merck & Co/MSD’s KEYTRUDA is granted the go-ahead for use in patients with high-risk early-stage or locally advanced TBNC. The National Institute for Health and Care Excellence (NICE) has recommended the use of KEYTRUDA (pembrolizumab) as an option with chemotherapy for neoadjuvant, and alone as adjuvant treatment afte

Patients 111

Patients Leads Pharma 111

Advertiser: ZoomInfo

In this eBook, we’ll run through real-world examples that show how RevOps teams can benefit from modern solutions for the access, management, and activation of their GTM data. Whether you need to improve lead response times, boost adoption of core tools, improve lead qualification, or target and automate your GTM motions, you’ll find examples of how revenue teams are solving some of the toughest problems in modern business.

Leads

Pharmaceutical Technology

NOVEMBER 9, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech’s bivalent Covid-19 booster vaccine that targets the SARS-CoV-2 virus’ original strain and the Omicron BA.4 and BA.5 sub-variants. Indicated for usage as a booster in people aged 12 years and older, the modified vaccine is the second bivalent shot of the companies to obtain approval in the region.

Medicine 105

Medicine Side effects Safety Pharmaceutical 105

Fierce Pharma

NOVEMBER 11, 2022

Viatris executive charged in insider trading scheme that allegedly netted $7.2 million. kdunleavy. Fri, 11/11/2022 - 11:30.

240

240

MedCity News

NOVEMBER 7, 2022

The hogwash started in The Wall Street Journal with a contrarian take on a recent KPMG technology report. But cloud operates in a fundamentally different paradigm from the IT infrastructure of the past, and embracing big change is rarely free or easy. But the rewards of evolving are obvious and far too great to ignore.

Healthcare 108

Healthcare Healthcare 108

pharmaphorum

NOVEMBER 7, 2022

In this new segment from pharmaphorum, we collect the most significant hirings, firings, and recruitment stories from across the industry. This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . Ben Grabski, Lumeris. Lumeris, a value-based care managed services operator for health systems, has appointed Ben Grabski as chief financial officer.

Pharmaceutical 105

Pharmaceutical Pharma Medicine Healthcare 105

Advertiser: ZoomInfo

Consolidating your tech stack is an effective cost-saving measure that drives GTM efficiency and adds value to your enterprise. With a cohesive, integrated tech stack, your revenue teams can deliver an excellent customer experience that sets you up to win faster than your competitors.